| alpha-2a interferon |
recurrent rectal cancer |
METHODS AND MATERIALS: In this Phase I pilot study, patients with locally advanced, unresectable, or recurrent rectal cancer with or without distant metastases received external beam pelvic radiotherapy over 5 to 6 weeks combined with escalating doses of |
9069300 |
Human |
| alpha-2a interferon |
kasabach-merritt syndrome |
Spindle cell (Kaposiform) hemangioendothelioma with Kasabach-Merritt syndrome in an infant: successful treatment with alpha-2A interferon. |
9121401 |
Human |
| alpha-2a interferon |
hemangioendothelioma |
Spindle cell (Kaposiform) hemangioendothelioma with Kasabach-Merritt syndrome in an infant: successful treatment with alpha-2A interferon. |
9121401 |
Human |
| alpha-2a interferon |
essential thrombocythemia |
Alpha-2a interferon therapy and antibody formation in patients with essential thrombocythemia and polycythemia vera with thrombocytosis. |
7864024 |
Human |
| alpha-2a interferon |
polycythemia vera |
Alpha-2a interferon therapy and antibody formation in patients with essential thrombocythemia and polycythemia vera with thrombocytosis. |
7864024 |
Human |
| alpha-2a interferon |
mediastinal tumors |
Epithelioid hemangioendothelioma and other vascular mediastinal tumors: a role for alpha-2a interferon? |
12902133 |
Human |
| alpha-2a interferon |
epithelioid hemangioendothelioma |
Epithelioid hemangioendothelioma and other vascular mediastinal tumors: a role for alpha-2a interferon? |
12902133 |
Human |
| alpha-2a interferon |
chronic myeloproliferative disorders |
Twenty-one patients with chronic myeloproliferative disorders, eleven with polycythemia vera (PV) and ten with essential thrombocythemia (ET), were treated with small doses of alpha-2a interferon (IFN). |
2055565 |
Human |
| ifnalpha2a |
tumors |
These data indicate that the tumor-homing peptide (NGR) can enhance the therapeutic efficacy of IFN-alpha2a against tumors. |
17354103 |
Human |
| ifnalpha2a |
tumor |
These data indicate that the tumor-homing peptide (NGR) can enhance the therapeutic efficacy of IFN-alpha2a against tumors. |
17354103 |
Human |
| cytokine |
b-cell chronic lymphocytic leukemia |
Alpha 2-interferon in B-cell chronic lymphocytic leukemia: clinical response, serum cytokine levels, and immunophenotype modulation. |
7680399 |
Human |
| cytokine |
non-melanoma skin cancers |
Interferon-alpha (IFN-alpha) is a cytokine that is effective in the treatment of a variety of cancers, including non-melanoma skin cancers. |
7705922 |
NA |
| cytokine |
cervical intraepithelial neoplasia |
The expression of genes coding for inflammatory cytokine interleukin-1-alpha (IL-1 alpha), IL-6, interferon-gamma and tumor necrosis factor-alpha from 15 normal cervix, 11 cervical intraepithelial neoplasia and 13 cervical cancer tissues was investigated. |
7575522 |
Human |
| cytokine |
stage iv colorectal cancer |
A total of 29 patients with stage IV colorectal cancer were entered into a phase II trial of bolus interleukin-2 (IL-2) and interferon-alpha (IFN alpha) (3 x 10(6) U/m2 of each cytokine given i.v. q8h x 15 doses and repeated in 2 weeks). |
8680653 |
NA |
| cytokine |
tumor |
The tumorigenicity of transplantable tumor cells in mice is reduced by transduction with cytokine genes, including IFN-alpha and interleukin (IL) 12. |
9865738 |
Mouse |
| ifna |
glioblastomas |
Human malignant gliomas (glioblastomas and anaplastic astrocytomas) are the most frequent brain tumors and are associated with a variety of genetic alterations including retinoblastoma (RB) and p53 gene mutations, loss of interferon alpha and beta (IFNA, |
1501894 |
Human |
| ifna |
malignant gliomas |
Human malignant gliomas (glioblastomas and anaplastic astrocytomas) are the most frequent brain tumors and are associated with a variety of genetic alterations including retinoblastoma (RB) and p53 gene mutations, loss of interferon alpha and beta (IFNA, |
1501894 |
Human |
| ifna |
retinoblastoma |
Human malignant gliomas (glioblastomas and anaplastic astrocytomas) are the most frequent brain tumors and are associated with a variety of genetic alterations including retinoblastoma (RB) and p53 gene mutations, loss of interferon alpha and beta (IFNA, |
1501894 |
Human |
| ifna |
brain tumors |
Human malignant gliomas (glioblastomas and anaplastic astrocytomas) are the most frequent brain tumors and are associated with a variety of genetic alterations including retinoblastoma (RB) and p53 gene mutations, loss of interferon alpha and beta (IFNA, |
1501894 |
Human |
| ifna |
anaplastic astrocytomas |
Human malignant gliomas (glioblastomas and anaplastic astrocytomas) are the most frequent brain tumors and are associated with a variety of genetic alterations including retinoblastoma (RB) and p53 gene mutations, loss of interferon alpha and beta (IFNA, |
1501894 |
Human |
| ifna |
nsclc |
To define the location and extent of deletions of 9p in NSCLC and MM, Southern blot analyses on six NSCLC and five MM cell lines using molecular probes to 9p loci (IFNA, IFNB1, D9S3, and D9S19) were performed, and DNA dosage was determined by densitometry |
7688555 |
Human |
| ifna |
adenocarcinoma of the esophagus |
Since esophageal cancer shares characteristics with some of the above tumor types, we performed a detailed examination of 60 patients with squamous cell carcinoma or adenocarcinoma of the esophagus for LOH at loci D9S162, IFNA, D9S171, D9S126, D9S104, D9S |
7954453 |
Human |
| ifna |
esophageal squamous-cell carcinoma |
By the microsatellite assay, two types of genetic alterations, loss of heterozygosity (LOH) and replication error (RER), were examined using 7 dinucleotide repeat markers [D3S1317 (3p26); CI3-1169 (3p25); CI3-946 (3p25); D3S1255 (3p24.2-25); CI3-771 (3p21 |
7850805 |
Human |
| ifna |
adenomas |
In order to elucidate the significance of the adenoma-carcinoma sequence in gastric carcinogenesis from a genetic point of view, we examined microsatellite alterations (replication error and loss of heterozygosity) on chromosomes 2p (D2S123), 3p (D3S1317) |
7728762 |
Human |
| ifna |
nasopharyngeal carcinoma |
Nasopharyngeal carcinoma, which is very frequent in southern China, has in previous investigations been found to be associated with a number of risk factors, including a disease susceptibility gene linked to the HLA-region, p53 alleles and deletions of th |
9111194 |
Human |
| ifna |
metastatic bladder cancers |
DESIGN: The authors examined the pattern of allelic loss with polymorphic microsatellite markers on chromosome 9p21 (D9S161, D9S171, IFNA), regions of putative tumor suppressor gene p16, and on chromosome 17p13 (TP53), the p53 locus, in matched primary an |
11520271 |
Human |
| ifna |
metastatic cancer |
The frequency of allelic loss in matched metastatic cancer was 100% with D9S161, 62% with D9S171, 71% with IFNA, and 80% with TP53. |
11520271 |
Human |
| ifna |
recurrent pituitary tumours |
In contrast, however, the metastatic lesion showed a loss-to-retention pattern at two distinct loci (IFNA and D22S156) compared to the primary and recurrent pituitary tumours. |
11678840 |
Human |
| ifna |
ampullary carcinoma |
Sixty-two point five percent (5/8) of ampullary carcinoma cases showed loss of heterozygosity at one or more of the loci, frequent site of loss being D9S942 (42.9%) and the next most frequent being IFNA (37.5%) and D9S171 (37.5%). |
11780432 |
Human |
| ifna |
benign melanocytic nevi |
We have analyzed 54 benign melanocytic nevi and 6 DMN for loss of heterozygosity (LOH) at microsatellite markers D9S171, IFNA, D9S270, D9S265. |
12079204 |
Human |
| ifna |
small-cell carcinoma |
We examined five polymorphic microsatellite markers located on chromosome 3p25-26 (D3S3050), chromosome 9p21 (IFNA and D9S171), chromosome 9q32-33 (D9S177), and chromosome 17p13 (TP53) in 20 patients with small-cell carcinoma of the urinary bladder and co |
15855652 |
Human |
| ifna |
urothelial carcinoma |
We examined five polymorphic microsatellite markers located on chromosome 3p25-26 (D3S3050), chromosome 9p21 (IFNA and D9S171), chromosome 9q32-33 (D9S177), and chromosome 17p13 (TP53) in 20 patients with small-cell carcinoma of the urinary bladder and co |
15855652 |
Human |
| interferon alpha-2 |
metastatic renal cell cancer |
Prognostic indicators for response to therapy and survival in patients with metastatic renal cell cancer treated with interferon alpha-2 beta and vinblastine. |
8804488 |
Human |
| interferon alpha-2 |
squamous cell carcinoma of the cervix |
Recent publications report on a synergistic effect of combination therapy using 13-cis-retinoic acid and interferon alpha-2 a in the treatment of squamous cell carcinoma of the cervix. |
9036064 |
Human |
| alpha-2a interferon |
papillomatosis |
[Antibodies to alpha-2A interferon in children with juvenile respiratory papillomatosis] Follow-up of 36 JRP children and 12 controls (as shown by solid-phase enzyme immunoassay) has revealed that antibodies to IFN-alpha 2a with titers 1:20 to 1:1280 were |
7502448 |
Human |
| ifn-alpha-2a |
neuroendocrine tumors |
METHODS. To verify the clinical activity of IFN, 49 evaluable patients with advanced stage low- and intermediate-grade neuroendocrine tumors were treated with recombinant IFN-alpha-2a at a daily dose of 6 x 10(6) IU intramuscularly for 8 weeks, and 3 time |
7693327 |
Human |
| ifn-alpha-2a |
carcinoid syndrome |
CONCLUSIONS. The use of recombinant IFN-alpha-2a at these doses is well-tolerated and effective in controlling carcinoid syndrome (complete remission plus partial remission, 64%), although it has limited activity on tumor growth inhibition. |
7693327 |
Human |
| ifn-alpha-2a |
hairy cell leukemia |
To explore the relationship between anti-interferon-alpha (anti-IFN-alpha) antibodies and loss of clinical responsiveness to IFN-alpha treatment, we examined sera from 59 patients with hairy cell leukemia who responded to therapy with recombinant IFN-alph |
2070058 |
Human |
| ifn-alpha-2a |
kaposi's sarcoma |
Anti-interferon (IFN)-alpha antibodies were determined in the serum of 28 patients treated with high-dose human recombinant IFN-alpha-2a for AIDS-associated Kaposi's sarcoma. |
2088534 |
Human |
| ifn alpha 2a |
chronic myeloid leukaemia (cml) |
Neutralizing anti-IFN alpha antibodies (nIFN alpha Abs) occur in a significant proportion of patients with hairy cell leukaemia, hepatitis or solid tumours treated with recombinant IFN alpha (IFN alpha 2a or IFN alpha 2b), but information on their inciden |
8759890 |
Human |
| ifn alpha 2a |
hairy cell leukaemia |
Neutralizing anti-IFN alpha antibodies (nIFN alpha Abs) occur in a significant proportion of patients with hairy cell leukaemia, hepatitis or solid tumours treated with recombinant IFN alpha (IFN alpha 2a or IFN alpha 2b), but information on their inciden |
8759890 |
Human |
| ifn alpha 2a |
solid tumours |
Neutralizing anti-IFN alpha antibodies (nIFN alpha Abs) occur in a significant proportion of patients with hairy cell leukaemia, hepatitis or solid tumours treated with recombinant IFN alpha (IFN alpha 2a or IFN alpha 2b), but information on their inciden |
8759890 |
Human |
| ifn alpha 2a |
cml |
This data shows that a significant proportion of Ph+ CML patients receiving treatment with IFN alpha 2a can develop neutralizing antibodies and that these antibodies are associated with a loss of IFN alpha 2a efficacy. |
8759890 |
Human |
| ifnalpha2a |
diffuse malignant mesothelioma (dmm) |
PURPOSE: To assess the tolerance, toxicity, and antitumoral activity of the weekly combination of cisplatin (CDDP) and interferon alfa-2a (IFNalpha2a) in advanced diffuse malignant mesothelioma (DMM). |
8622036 |
Human |
| ifnalpha2a |
refractory cancer |
PATIENTS AND METHODS: Thirty-three children with refractory cancer (stratified by age, < or = 12 and > 12 years) were treated with ATRA 3 consecutive days per week and IFN-alpha2a 3 x 10(6) U/m2 5 consecutive days per week, both repeated weekly. |
9363862 |
Human |
| ifnalpha2a |
stage ii melanoma |
Using the trial demonstrating that interferonalpha-2a (IFNalpha-2a) is efficacious as adjuvant therapy in stage II melanoma, we evaluate its outcomes and economic consequences. |
11239759 |
Human |
| ifnalpha2a |
stage ii melanoma |
Cost-effectiveness of IFNalpha-2a in stage II melanoma compares favourably with estimates for widely used therapies in the oncological field. |
11239759 |
Human |
| ifnalpha2a |
liver cancer |
CONCLUSION: IFN-alpha2a enhanced the antitumor effect of capecitabine on HCC in nude mice, which might be ascribed to the up-regulation of TP expression in liver cancer tissues by IFN-alpha2a. |
15071737 |
Mouse |
| ifnalpha2a |
tumor |
The cleavage pattern of rRNA induced by ECyd was similar and the cleavage sites were identical to those cleaved by RNase L. Additionaly, apoptosis induced by ECyd was elevated following the protein expression of RNase L in the tumor cells when treated wit |
17150838 |
Human |
| ifnalpha2a |
head and neck cancer |
BACKGROUND: We have previously conducted phase II trials with a combination of 13-cis-retinoic acid (13-cRA), interferon-alpha2a (IFN-alpha2a), and alpha-tocopherol (alpha-TF) in patients with advanced oral premalignant lesions and locally advanced head a |
17163463 |
Human |
| ifnalpha2a |
metastatic renal cell carcinoma |
[Immunotherapy of metastatic renal cell carcinoma with interleukin-2, interferon-alpha2a and erythropoietin-beta] BACKGROUND: The combination of interferon-alpha2a (IFN-alpha2a) and interleukin-2 (IL-2) induces objective responses in patients with metasta |
17356836 |
Human |
| ifnalpha2a |
metastatic renal cell carcinoma (mrcc) |
[Immunotherapy of metastatic renal cell carcinoma with interleukin-2, interferon-alpha2a and erythropoietin-beta] BACKGROUND: The combination of interferon-alpha2a (IFN-alpha2a) and interleukin-2 (IL-2) induces objective responses in patients with metasta |
17356836 |
Human |
| ifnalpha2a |
capillary hemangioma |
PURPOSE: To report the use of a combination of low-dose cyclophosphamide and interferon alfa 2a (IFNalpha2a) for the treatment of orbital juvenile capillary hemangioma. |
17337066 |
Human |
| ifnalpha2a |
advanced colorectal cancer |
EXPERIMENTAL DESIGN: We studied 188 patients enrolled on protocol E2290, a five-arm trial comparing 5-FU, 5-FU in combination with N-phosphonoacetyl-l-aspartic acid, oral leucovorin, i.v. leucovorin, or IFNalpha-2a in patients with advanced colorectal can |
17947473 |
Human |
| ifnalpha2a |
renal cell cancer |
Individual sensitivity of blood neutrophils to IFN-alpha2a was studied in vitro in patients with renal cell cancer before and after the first course of reaferon therapy. |
18256759 |
Human |
| ifn-alpha-2a |
melanoma |
Thirty-three melanoma patients were prospectively investigated during adjuvant treatment with IFN-alpha-2a/2b (3 x 3 Mio units/wk). |
17414324 |
Human |
| ifn-alpha-2a |
brain metastases |
METHODS: Twenty-eight patients with stage IV melanoma without brain metastases were treated with DTIC (at a dose of 850 mg/m(2) every 3 weeks) combined with weekly pegylated IFN-alpha-2a at a dose of 180 microg. |
18615619 |
Human |
| ifn-alpha-2a |
stage iv melanoma |
METHODS: Twenty-eight patients with stage IV melanoma without brain metastases were treated with DTIC (at a dose of 850 mg/m(2) every 3 weeks) combined with weekly pegylated IFN-alpha-2a at a dose of 180 microg. |
18615619 |
Human |
| ifn alpha 2a |
chronic myeloid leukaemia |
Neutralizing anti-IFN alpha antibodies (nIFN alpha Abs) occur in a significant proportion of patients with hairy cell leukaemia, hepatitis or solid tumours treated with recombinant IFN alpha (IFN alpha 2a or IFN alpha 2b), but information on their inciden |
8759890 |
Human |
| ifnalpha2a |
diffuse malignant mesothelioma |
PURPOSE: To assess the tolerance, toxicity, and antitumoral activity of the weekly combination of cisplatin (CDDP) and interferon alfa-2a (IFNalpha2a) in advanced diffuse malignant mesothelioma (DMM). |
8622036 |
Human |
